# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 13, "Diabetes Care", "", "<http://ctro/data#Publication_63056> <http://ctro/data#hasJournal> \"Diabetes Care\"."
1, PublicationYear, 16, 20, "2014", "", "<http://ctro/data#Publication_63056> <http://ctro/data#hasPublicationYear> \"2014\"."
96, Title, 101, 237, "Efficacy and safety of oral methazolamide in patients with type 2 diabetes : a 24 - week , placebo - controlled , double - blind study .", "", "<http://ctro/data#Publication_63056> <http://ctro/data#hasTitle> \"Efficacy and safety of oral methazolamide in patients with type 2 diabetes : a 24 - week , placebo - controlled , double - blind study .\"."
2, Oral, 124, 128, "oral", "", 
79642, Methazolamide, 129, 142, "methazolamide", "", 
10, Type2Diabetes, 160, 175, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_63063> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
13, Duration, 180, 189, "24 - week", "", "<http://ctro/data#ClinicalTrial_63063> <http://ctro/data#hasCTduration> \"24 - week\"."
15, Placebo, 192, 199, "placebo", "", 
18, DoubleBlind, 215, 229, "double - blind", "", 
19, Author, 238, 248, "Simpson RW", "", "<http://ctro/data#Publication_63056> <http://ctro/data#hasAuthor> \"Simpson RW\"."
20, Author, 257, 269, "Nicholson GC", "", "<http://ctro/data#Publication_63056> <http://ctro/data#hasAuthor> \"Nicholson GC\"."
21, Author, 278, 288, "Proietto J", "", "<http://ctro/data#Publication_63056> <http://ctro/data#hasAuthor> \"Proietto J\"."
22, Author, 297, 304, "Sarah A", "", "<http://ctro/data#Publication_63056> <http://ctro/data#hasAuthor> \"Sarah A\"."
23, Author, 313, 323, "Sanders KM", "", "<http://ctro/data#Publication_63056> <http://ctro/data#hasAuthor> \"Sanders KM\"."
24, Author, 332, 342, "Phillips G", "", "<http://ctro/data#Publication_63056> <http://ctro/data#hasAuthor> \"Phillips G\"."
25, Author, 351, 361, "Chambers J", "", "<http://ctro/data#Publication_63056> <http://ctro/data#hasAuthor> \"Chambers J\"."
26, Author, 370, 381, "MacGinley R", "", "<http://ctro/data#Publication_63056> <http://ctro/data#hasAuthor> \"MacGinley R\"."
27, Author, 390, 398, "Orford N", "", "<http://ctro/data#Publication_63056> <http://ctro/data#hasAuthor> \"Orford N\"."
28, Author, 407, 415, "Walder K", "", "<http://ctro/data#Publication_63056> <http://ctro/data#hasAuthor> \"Walder K\"."
29, Author, 424, 434, "Krippner G", "", "<http://ctro/data#Publication_63056> <http://ctro/data#hasAuthor> \"Krippner G\"."
30, Author, 443, 450, "Skoff K", "", "<http://ctro/data#Publication_63056> <http://ctro/data#hasAuthor> \"Skoff K\"."
31, Author, 459, 468, "Wacher VJ", "", "<http://ctro/data#Publication_63056> <http://ctro/data#hasAuthor> \"Wacher VJ\"."
32, Australia, 546, 555, "Australia", "", 
33, Australia, 681, 690, "Australia", "", 
34, Australia, 783, 792, "Australia", "", 
35, Australia, 885, 894, "Australia", "", 
36, Australia, 944, 953, "Australia", "", 
37, Australia, 1134, 1143, "Australia", "", 
38, Australia, 1207, 1216, "Australia", "", 
39, Australia, 1280, 1289, "Australia", "", 
40, ObjectiveDescription, 1334, 1431, "To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes .", "", "<http://ctro/data#ClinicalTrial_63063> <http://ctro/data#hasObjectiveDescription> \"To evaluate the safety and efficacy of methazolamide as a potential therapy for type 2 diabetes .\"."
79643, Methazolamide, 1373, 1386, "methazolamide", "", 
11, Type2Diabetes, 1414, 1429, "type 2 diabetes", "", 
41, DoubleBlind, 1467, 1481, "double - blind", "", 
42, Placebo, 1484, 1491, "placebo", "", 
43, Randomized, 1511, 1521, "randomized", "", "<http://ctro/data#ClinicalTrial_63063> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
44, NumberPatientsCT, 1522, 1524, "76", "", "<http://ctro/data#ClinicalTrial_63063> <http://ctro/data#hasNumberPatientsCT> \"76\"."
45, Oral, 1537, 1541, "oral", "", "<http://ctro/data#Medication_63139> <http://ctro/data#hasDeliveryMethod> <http://ctro/data#Oral>."
79649, Methazolamide, 1542, 1555, "methazolamide", "", "<http://ctro/data#Medication_63139> <http://ctro/data#hasDrug> <http://ctro/data#Methazolamide>."
46, DoseValue, 1558, 1560, "40", "", "<http://ctro/data#Medication_63139> <http://ctro/data#hasDoseValue> \"40\"."
47, mg, 1561, 1563, "mg", "", "<http://ctro/data#Medication_63139> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
48, Frequency, 1564, 1575, "b . i . d .", "", "<http://ctro/data#Intervention_63127> <http://ctro/data#hasFrequency> \"b . i . d .\"."
16, Placebo, 1581, 1588, "placebo", "", "<http://ctro/data#Medication_63146> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
14, Duration, 1593, 1601, "24 weeks", "", 
79645, Methazolamide, 1639, 1652, "methazolamide", "", 
49, Placebo, 1669, 1676, "placebo", "", 
50, HbA1c, 1702, 1707, "HbA1c", "", 
54, TimePoint, 1713, 1721, "baseline", "", 
55, TimePoint, 1728, 1736, "24 weeks", "", 
51, HbA1c, 1741, 1746, "HbA1c", "", 
140, Mean, 1761, 1765, "Mean", "", "<http://ctro/data#Mean_63196> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_63194> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_63196>."
56, TimePoint, 1771, 1779, "baseline", "", 
52, HbA1c, 1780, 1785, "HbA1c", "", "<http://ctro/data#Endpoint_63194> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
57, BaseLineValue, 1790, 1795, "7 . 1", "", "<http://ctro/data#Outcome_63208> <http://ctro/data#hasBaselineValue> \"7 . 1\"."
59, SdDevBL, 1798, 1803, "0 . 7", "", "<http://ctro/data#Outcome_63208> <http://ctro/data#hasSdDevBL> \"0 . 7\"."
61, Percentage, 1804, 1805, "%", "", "<http://ctro/data#Endpoint_63194> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
58, BaseLineValue, 1808, 1810, "54", "", 
60, SdDevBL, 1813, 1814, "5", "", 
79864, Millimoles_per_mole, 1815, 1825, "mmol / mol", "", 
65, NumberPatientsArm, 1832, 1834, "37", "", "<http://ctro/data#Arm_63107> <http://ctro/data#hasNumberPatientsArm> \"37\"."
67, BaseLineValue, 1841, 1846, "7 . 4", "", "<http://ctro/data#Outcome_63235> <http://ctro/data#hasBaselineValue> \"7 . 4\"."
69, SdDevBL, 1849, 1854, "0 . 6", "", "<http://ctro/data#Outcome_63235> <http://ctro/data#hasSdDevBL> \"0 . 6\"."
62, Percentage, 1855, 1856, "%", "", 
68, BaseLineValue, 1859, 1861, "57", "", 
70, SdDevBL, 1864, 1865, "5", "", 
79865, Millimoles_per_mole, 1866, 1876, "mmol / mol", "", 
66, NumberPatientsArm, 1883, 1885, "39", "", "<http://ctro/data#Arm_63117> <http://ctro/data#hasNumberPatientsArm> \"39\"."
79651, Methazolamide, 1895, 1908, "methazolamide", "", 
17, Placebo, 1913, 1920, "placebo", "", 
79653, Methazolamide, 1945, 1958, "Methazolamide", "", 
53, HbA1c, 1993, 1998, "HbA1c", "", "<http://ctro/data#Endpoint_63194> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
71, Reduction, 2004, 2010, "0 . 39", "", "<http://ctro/data#Outcome_63208> <http://ctro/data#hasChangeValue> \"0 . 39\"."
73, Percentage, 2011, 2012, "%", "", 
74, ConfIntervalChangeValue, 2015, 2040, "95 % CI - 0 . 82 , 0 . 04", "", "<http://ctro/data#Outcome_63208> <http://ctro/data#hasConfIntervalChangeValue> \"95 % CI - 0 . 82 , 0 . 04\"."
76589, PValueChangeValue, 2043, 2053, "P < 0 . 05", "", "<http://ctro/data#Outcome_63208> <http://ctro/data#hasPValueChangeValue> \"P < 0 . 05\"."
72, Reduction, 2060, 2065, "4 . 3", "", 
79866, Millimoles_per_mole, 2066, 2076, "mmol / mol", "", 
75, ConfIntervalChangeValue, 2079, 2094, "- 9 . 0 , 0 . 4", "", 
78, HbA1c_target, 2153, 2168, "HbA1c â‰¤ 6 . 5 %", "", "<http://ctro/data#Endpoint_63262> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c_target>."
166, Percentage, 2167, 2168, "%", "", 
79867, Millimoles_per_mole, 2174, 2184, "mmol / mol", "", 
174, PercentageAffected, 2192, 2193, "8", "", "<http://ctro/data#Outcome_63294> <http://ctro/data#hasPercentageAffected> \"8\"."
79, PercentageAffected, 2197, 2199, "33", "", "<http://ctro/data#Outcome_63267> <http://ctro/data#hasPercentageAffected> \"33\"."
81, EndPointDescription, 2225, 2249, "alanine aminotransferase", "", "<http://ctro/data#EndPointDescription_63322> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_63321> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_63322>."
80, Reduction, 2254, 2256, "10", "", "<http://ctro/data#Outcome_63331> <http://ctro/data#hasChangeValue> \"10\"."
84, BioAndMedicalUnit, 2257, 2266, "units / L", "", "<http://ctro/data#BioAndMedicalUnit_63324> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#BioAndMedicalUnit>. <http://ctro/data#Endpoint_63321> <http://ctro/data#hasBaselineUnit> <http://ctro/data#BioAndMedicalUnit_63324>."
82, BodyWeight, 2275, 2281, "weight", "", "<http://ctro/data#Endpoint_63326> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#BodyWeight>."
83, RelativeReduction, 2289, 2290, "2", "", "<http://ctro/data#Outcome_63358> <http://ctro/data#hasRelativeChangeValue> \"2\"."
100521, SubGroupDescription, 2298, 2328, "metformin - cotreated patients", "", "<http://ctro/data#Outcome_63208> <http://ctro/data#hasSubGroupDescription> \"metformin - cotreated patients\". <http://ctro/data#Outcome_63235> <http://ctro/data#hasSubGroupDescription> \"metformin - cotreated patients\". <http://ctro/data#Outcome_63267> <http://ctro/data#hasSubGroupDescription> \"metformin - cotreated patients\". <http://ctro/data#Outcome_63294> <http://ctro/data#hasSubGroupDescription> \"metformin - cotreated patients\". <http://ctro/data#Outcome_63331> <http://ctro/data#hasSubGroupDescription> \"metformin - cotreated patients\". <http://ctro/data#Outcome_63358> <http://ctro/data#hasSubGroupDescription> \"metformin - cotreated patients\"."
85, Metformin, 2298, 2307, "metformin", "", 
79655, Methazolamide, 2345, 2358, "Methazolamide", "", 
87, ConclusionComment, 2345, 2465, "Methazolamide is the archetype for a new intervention in type 2 diabetes with clinical benefits beyond glucose control .", "", "<http://ctro/data#ClinicalTrial_63063> <http://ctro/data#hasConclusionComment> \"Methazolamide is the archetype for a new intervention in type 2 diabetes with clinical benefits beyond glucose control .\"."
12, Type2Diabetes, 2402, 2417, "type 2 diabetes", "", 
88, PMID, 2692, 2700, "25125506", "", "<http://ctro/data#Publication_63056> <http://ctro/data#hasPMID> \"25125506\"."
